Michael W. Becker

11.9k total citations · 3 hit papers
137 papers, 7.6k citations indexed

About

Michael W. Becker is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Michael W. Becker has authored 137 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Hematology, 40 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Michael W. Becker's work include Acute Myeloid Leukemia Research (46 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Cancer Genomics and Diagnostics (12 papers). Michael W. Becker is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Cancer Genomics and Diagnostics (12 papers). Michael W. Becker collaborates with scholars based in United States, Germany and United Kingdom. Michael W. Becker's co-authors include Michael F. Clarke, Irving L. Weissman, Dalong Qian, Craig T. Jordan, Sean J. Morrison, Mark J. Kiel, In-Kyung Park, Jane L. Liesveld, Iduna Fichtner and John M. Ashton and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Michael W. Becker

134 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

2003 1.5k citations Dalong Qian, Michael W. Becker et al. Nature profile →
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

2013 943 citations John M. Ashton, Shanshan Pei et al. profile →
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels

2019 254 citations Michael W. Becker, Gail J. Roboz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael W. Becker United States	38	4.2k	2.3k	2.2k	1.4k	909	137	7.6k
William Matsui United States	54	6.1k 1.5×	2.5k 1.1×	5.3k 2.4×	1.7k 1.2×	1.7k 1.8×	154	10.8k
Jane L. Liesveld United States	47	2.8k 0.7×	3.7k 1.6×	2.3k 1.1×	776 0.6×	1.6k 1.8×	252	8.3k
Justus Duyster Germany	52	3.9k 0.9×	3.5k 1.5×	2.4k 1.1×	1.2k 0.8×	1.5k 1.6×	261	9.0k
Andrew P. Mazar United States	53	3.5k 0.8×	1.3k 0.5×	2.3k 1.0×	3.0k 2.2×	908 1.0×	176	7.8k
Delong Liu United States	51	3.9k 0.9×	1.3k 0.6×	3.9k 1.8×	871 0.6×	1.7k 1.8×	189	9.1k
Daniela S. Krause United States	30	2.8k 0.7×	1.8k 0.8×	1.6k 0.7×	536 0.4×	1.3k 1.5×	74	6.0k
Itaru Matsumura Japan	39	2.5k 0.6×	2.0k 0.9×	1.4k 0.6×	503 0.4×	1.1k 1.2×	216	5.5k
Richard B. Lock Australia	53	5.1k 1.2×	1.6k 0.7×	2.8k 1.3×	1.2k 0.9×	1.0k 1.1×	260	8.7k
Bruce A. Keyt United States	31	5.1k 1.2×	1.7k 0.7×	950 0.4×	1.6k 1.2×	599 0.7×	79	9.9k
Mark A. Dawson Australia	33	5.7k 1.4×	1.2k 0.5×	1.3k 0.6×	1.2k 0.9×	700 0.8×	86	7.5k

Countries citing papers authored by Michael W. Becker

Since Specialization

Citations

This map shows the geographic impact of Michael W. Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Becker more than expected).

Fields of papers citing papers by Michael W. Becker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Becker. The network helps show where Michael W. Becker may publish in the future.

Co-authorship network of co-authors of Michael W. Becker

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Becker. A scholar is included among the top collaborators of Michael W. Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Becker. Michael W. Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vezzali, Enrico, Michael W. Becker, Marjolein van Heerden, et al.. (2025). European Society of Toxicologic Pathology—Pathology 2.0 Mass Spectrometry Imaging Special Interest Group: Mass Spectrometry Imaging in Diagnostic and Toxicologic Pathology for Label-Free Detection of Molecules—From Basics to Practical Applications. Toxicologic Pathology. 53(1). 130–158.

Kawano, Hiroki, Yuko Kawano, Yu Chen, et al.. (2023). Mitochondrial Transfer to Host Cells from Ex Vivo Expanded Donor Hematopoietic Stem Cells. Cells. 12(11). 1473–1473. 3 indexed citations

Kim, Hye Sung, Tzu‐Chieh Ho, Moshe J. Willner, et al.. (2022). Dendritic cell-mimicking scaffolds for ex vivo T cell expansion. Bioactive Materials. 21. 241–252. 15 indexed citations

Ho, Tzu‐Chieh, Hye Sung Kim, Yumei Chen, et al.. (2021). Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy. Science Advances. 7(21). 93 indexed citations

Duy, Cihangir, Meng Li, Matt Teater, et al.. (2021). Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discovery. 11(6). 1542–1561. 153 indexed citations

Smoller, Bruce R., et al.. (2021). Oral white lesion in patients post-hematopoietic stem cell transplantation: a case series demonstrating the diagnostic dilemma. Supportive Care in Cancer. 29(12). 7999–8007. 6 indexed citations

Weigand, Tim, Florian Colbatzky, Sven F. Garbade, et al.. (2020). A Global Cndp1-Knock-Out Selectively Increases Renal Carnosine and Anserine Concentrations in an Age- and Gender-Specific Manner in Mice. International Journal of Molecular Sciences. 21(14). 4887–4887. 11 indexed citations

Stevens, Brett M., Courtney L. Jones, Daniel A. Pollyea, et al.. (2020). Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer. 1(12). 1176–1187. 178 indexed citations

Azadniv, Mitra, Jason R. Myers, Helene R. McMurray, et al.. (2019). Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia. 34(2). 391–403. 71 indexed citations

10.

Calvi, Laura M., Allison J. Li, & Michael W. Becker. (2019). What is the role of the microenvironment in MDS?. Best Practice & Research Clinical Haematology. 32(4). 101113–101113. 7 indexed citations

11.

Silva, Andreia, Tim Robinson, Angélica Santiago-Gómez, et al.. (2018). Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clinical Cancer Research. 24(10). 2452–2463. 42 indexed citations

12.

Ho, Tzu‐Chieh, Mark W. LaMere, Brett M. Stevens, et al.. (2016). Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 128(13). 1671–1678. 166 indexed citations

13.

Hunter, Bradley D., Megan M. Herr, Ferdous M. Barlaskar, et al.. (2016). Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma & Leukemia. 17(3). 145–151. 9 indexed citations

14.

Balderman, Sophia, Allison J. Li, Corey M. Hoffman, et al.. (2015). Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. Blood. 127(5). 616–625. 67 indexed citations

15.

Guzmán, Mónica L., Neng Yang, Krishan K. Sharma, et al.. (2014). Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics. 13(8). 1979–1990. 45 indexed citations

16.

Hammer, Stefanie, Anette Sommer, Iduna Fichtner, et al.. (2010). Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer. Clinical Cancer Research. 16(5). 1452–1465. 34 indexed citations

17.

Fichtner, Iduna, Jana Rolff, Richie Soong, et al.. (2008). Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers. Clinical Cancer Research. 14(20). 6456–6468. 227 indexed citations

18.

Park, Inkyung, et al.. (2008). Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature. 453(7192). 228–232. 131 indexed citations

19.

Pallua, Norbert, Hans‐Guenther Machens, Oliver H. Rennekampff, Michael W. Becker, & Alfred Berger. (1997). The Fasciocutaneous Supraclavicular Artery Island Flap for Releasing Postburn Mentosternal Contractures. Plastic & Reconstructive Surgery. 99(7). 1878–1884. 163 indexed citations

20.

Fichtner, Iduna, Regina Reszka, Michael C. Rudolph, et al.. (1993). Carboplatin-liposomes as activators of hematopoiesis.. PubMed. 5(2). 65–74. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact